183 related articles for article (PubMed ID: 37343908)
1. Stimuli-responsive cancer nanomedicines inhibit glycolysis and impair redox homeostasis.
Meng X; Wang L; Zhao N; Zhao D; Shen Y; Yao Y; Jing W; Man S; Dai Y; Zhao Y
Acta Biomater; 2023 Sep; 167():374-386. PubMed ID: 37343908
[TBL] [Abstract][Full Text] [Related]
2. Tumor metabolism destruction via metformin-based glycolysis inhibition and glucose oxidase-mediated glucose deprivation for enhanced cancer therapy.
Meng X; Lu Z; Lv Q; Jiang Y; Zhang L; Wang Z
Acta Biomater; 2022 Jun; 145():222-234. PubMed ID: 35460908
[TBL] [Abstract][Full Text] [Related]
3. Synergistic glycolysis disturbance for cancer therapy by a MOF-based nanospoiler.
Zeng X; Ruan Y; Wang L; Deng J; Yan S
Biophys Rep; 2023 Jun; 9(3):134-145. PubMed ID: 38028149
[TBL] [Abstract][Full Text] [Related]
4. Biomimetic nanoplatform with H
Fu LH; Wu XY; He J; Qi C; Lin J; Huang P
Acta Biomater; 2023 May; 162():44-56. PubMed ID: 36934891
[TBL] [Abstract][Full Text] [Related]
5. A reactive oxygen species-replenishing coordination polymer nanomedicine disrupts redox homeostasis and induces concurrent apoptosis-ferroptosis for combinational cancer therapy.
Zhang Z; Pan Y; Cun JE; Li J; Guo Z; Pan Q; Gao W; Pu Y; Luo K; He B
Acta Biomater; 2022 Oct; 151():480-490. PubMed ID: 35926781
[TBL] [Abstract][Full Text] [Related]
6. Radiotherapy-mediated redox homeostasis-controllable nanomedicine for enhanced ferroptosis sensitivity in tumor therapy.
Lin Y; Chen X; Yu C; Xu G; Nie X; Cheng Y; Luan Y; Song Q
Acta Biomater; 2023 Mar; 159():300-311. PubMed ID: 36642338
[TBL] [Abstract][Full Text] [Related]
7. Coenzyme-depleting nanocarriers for enhanced redox cancer therapy under hypoxia.
Li Y; Liu M; Zheng Y; Wang Z; Zhao Y
J Colloid Interface Sci; 2023 Jul; 641():135-145. PubMed ID: 36931212
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of energy-producing pathways of HepG2 cells by 3-bromopyruvate.
Pereira da Silva AP; El-Bacha T; Kyaw N; dos Santos RS; da-Silva WS; Almeida FC; Da Poian AT; Galina A
Biochem J; 2009 Feb; 417(3):717-26. PubMed ID: 18945211
[TBL] [Abstract][Full Text] [Related]
9. Metabolic intervention liposome for targeting glutamine-addiction of breast cancer.
Wu M; Wang Q; Chen S; Zhou Z; Li J; Sun H; Liu J; Wang G; Zhou F; Sun M
J Control Release; 2022 Oct; 350():1-10. PubMed ID: 35907591
[TBL] [Abstract][Full Text] [Related]
10. Bioreducible exosomes encapsulating glycolysis inhibitors potentiate mitochondria-targeted sonodynamic cancer therapy via cancer-targeted drug release and cellular energy depletion.
Nguyen Cao TG; Truong Hoang Q; Kang JH; Kang SJ; Ravichandran V; Rhee WJ; Lee M; Ko YT; Shim MS
Biomaterials; 2023 Oct; 301():122242. PubMed ID: 37473534
[TBL] [Abstract][Full Text] [Related]
11. Efficacy-shaping nanomedicine by loading Calcium Peroxide into Tumor Microenvironment-responsive Nanoparticles for the Antitumor Therapy of Prostate Cancer.
Wu D; Zhu ZQ; Tang HX; Shi ZE; Kang J; Liu Q; Qi J
Theranostics; 2020; 10(21):9808-9829. PubMed ID: 32863961
[No Abstract] [Full Text] [Related]
12. Tailored Trojan horse nanocarriers for enhanced redox-responsive drug delivery.
Li Y; Feng S; Dai P; Liu F; Shang Y; Yang Q; Qin J; Yuchi Z; Wang Z; Zhao Y
J Control Release; 2022 Feb; 342():201-209. PubMed ID: 34998915
[TBL] [Abstract][Full Text] [Related]
13. 3-bromopyruvate and sodium citrate target glycolysis, suppress survivin, and induce mitochondrial-mediated apoptosis in gastric cancer cells and inhibit gastric orthotopic transplantation tumor growth.
Wang TA; Zhang XD; Guo XY; Xian SL; Lu YF
Oncol Rep; 2016 Mar; 35(3):1287-96. PubMed ID: 26708213
[TBL] [Abstract][Full Text] [Related]
14. Targeting Metabolic-Redox Circuits for Cancer Therapy.
Wang K; Jiang J; Lei Y; Zhou S; Wei Y; Huang C
Trends Biochem Sci; 2019 May; 44(5):401-414. PubMed ID: 30679131
[TBL] [Abstract][Full Text] [Related]
15. Targeting tumor energy metabolism via simultaneous inhibition of mitochondrial respiration and glycolysis using biodegradable hydroxyapatite nanorods.
Zhang H; Liu R; Wan P; You X; Li S; Liu Z; Wang Y; Han F; Hao J; Li Y
Colloids Surf B Biointerfaces; 2023 Jun; 226():113330. PubMed ID: 37141772
[TBL] [Abstract][Full Text] [Related]
16. CD44-specific nanoparticles for redox-triggered reactive oxygen species production and doxorubicin release.
Lin CW; Lu KY; Wang SY; Sung HW; Mi FL
Acta Biomater; 2016 Apr; 35():280-92. PubMed ID: 26853764
[TBL] [Abstract][Full Text] [Related]
17. Diselenium-linked dimeric prodrug nanomedicine breaking the intracellular redox balance for triple-negative breast cancer targeted therapy.
Chen M; Zhang M; Lu X; Li Y; Lu C
Eur J Pharm Biopharm; 2023 Dec; 193():16-27. PubMed ID: 37865134
[TBL] [Abstract][Full Text] [Related]
18. GSH-responsive degradable nanodrug for glucose metabolism intervention and induction of ferroptosis to enhance magnetothermal anti-tumor therapy.
Liao Z; Wen E; Feng Y
J Nanobiotechnology; 2024 Apr; 22(1):147. PubMed ID: 38570829
[TBL] [Abstract][Full Text] [Related]
19. Metabolic targeting of HIF-dependent glycolysis reduces lactate, increases oxygen consumption and enhances response to high-dose single-fraction radiotherapy in hypoxic solid tumors.
Leung E; Cairns RA; Chaudary N; Vellanki RN; Kalliomaki T; Moriyama EH; Mujcic H; Wilson BC; Wouters BG; Hill R; Milosevic M
BMC Cancer; 2017 Jun; 17(1):418. PubMed ID: 28619042
[TBL] [Abstract][Full Text] [Related]
20. p53-dependent glutamine usage determines susceptibility to oxidative stress in radioresistant head and neck cancer cells.
Chang HW; Lee M; Lee YS; Kim SH; Lee JC; Park JJ; Nam HY; Kim MR; Han MW; Kim SW; Kim SY
Cell Signal; 2021 Jan; 77():109820. PubMed ID: 33137455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
